Hematology · Acibadem Maslak Hospital, İstanbul Prof. Ahmet Öztürk, MD
✓ Medically verified profileProf. Ahmet Öztürk, MD
Prof. Ahmet Öztürk, MD is a hematology specialist in the Hematology Department at Acibadem Maslak Hospital in İstanbul. His work covers acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, bone marrow diseases, CAR T-cell therapy, anemia including iron deficiency anemia, immune thrombocytopenia, Henoch-Schönlein purpura and Castleman disease. He consults in Turkish and English.
Accepting international patientsAbout Prof. Ahmet Öztürk, MD
Prof. Ahmet Öztürk, MD is a hematology specialist in the Hematology Department at Acibadem Maslak Hospital in İstanbul. He has more than 42 years in medicine, and his clinical work covers acute and chronic leukemias, anemia, immune-mediated blood disorders, diseases of the bone marrow and CAR T-cell therapy.
Dr. Öztürk graduated from Gülhane Military Medical Academy Faculty of Medicine in 1984 and worked in Flight Medicine from 1985 to 1987. He completed his training in Internal Medicine in 1992 and in Hematology in 1995 at Gülhane Military Medical Academy. At GATA Haydarpaşa Training Hospital he was appointed Assistant Associate Professor in 1995, Associate Professor in 1997 and Professor in 2002, and he headed the Hematology Clinic there from 2002 to 2009. In 1997–1998 he worked at the Fred Hutchinson Cancer Research Center, Bone Marrow Transplantation Center. He joined Acıbadem Healthcare Services in 2011. He is a member of the Türk Hemotoloji Association. His published work includes studies on the treatment of acute myeloid leukemia and myelodysplastic syndrome with etoposide, thioguanine and cytarabine in elderly patients, on idiopathic thrombocytopenic purpura, and on prognostic factors in several solid tumors.
Clinical focus
Dr. Öztürk’s practice covers both malignant and non-malignant hematology. He evaluates and treats patients with acute lymphoblastic leukemia and acute myeloid leukemia, with chronic myeloid leukemia, and with other bone marrow diseases. CAR T-cell therapy is among the treatment approaches within his area of expertise. Because these conditions and treatments differ considerably in course and intensity, the suitability of any option is assessed individually on the basis of the diagnosis, the stage of disease and the patient’s general condition.
He also sees patients with anemia, including iron deficiency anemia, and with immune-related conditions such as immune thrombocytopenia and Henoch-Schönlein purpura. Castleman disease is also within his field. Assessment of these conditions typically begins with a careful history and a review of laboratory findings, so that further testing and treatment can be directed at the underlying cause.
How Dr. Öztürk works with international patients
Dr. Öztürk consults in Turkish and English, and interpreters can be arranged for patients who speak other languages. The Acibadem international patient team coordinates the collection of prior reports and imaging, arranges appointments and organizes the hospital visit. A first consultation typically covers the patient’s history and symptoms, a review of existing imaging and previous treatments, a clinical examination and a discussion of the options. Video consultation is available for international patients, which may be useful for an initial discussion of a case before traveling or for follow-up after treatment.
What Dr. Öztürk treats and performs
Each item opens the condition or treatment page with the care pathway for international patients.
Conditions treated
Procedures performed
Education, career and memberships
Education & training
Education
- 2002GATA Haydarpaşa Training Hospital / Professor
- 1997GATA Haydarpaşa Training Hospital / Associate Professor
- 1995Gülhane Military Medical Academy Hematology
- 1995GATA Haydarpaşa Training Hospital / Assistant Associate Professor
- 1992Gülhane Military Medical Academy Internal Medicine
- 1984Gülhane Military Medical Academy Faculty of Medicine
Career
Professional Experience
- 2011Acıbadem Healthcare Services
- 2002–2009GATA Haydarpaşa Training Hospital / Head of Hematology Clinic
- 1997–1998Fred Hutchinson Cancer Research Center, Bone Marrow Transplantation Center
- 1985–1987Flight Medicine
Memberships
Professional Memberships
- Türk Hemotoloji Association
Selected publications
Selected Publications
- Effects of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation. Respiration Kunter E,İlvan A,Özmen N,Demirer E,Öztürk A,Avşar K,Sayan Ö,Kartaloğlu Z
- Result of treatment of acute myeloid leukemia and myelodysplastic syndrome with etoposide, thioguanine, cytarabine (ETC) in elderly patients. Turk J Hematol 23;193-196,2006 A.Öztürk,A.Erikçi,Ö.Sayan.
- A role for leptin in idiopathic thrombocytopenic purpura? Platelets.17,501-502,2006. Akyol Alev, Ozturk Ahmet, Sayan Ozkan
- Investigation of the efficacy of irinotecan in patients with fluorosil-resistant advanced colorectal cancer. Clinical Sciences and Medicine O.Türken,M.Yaylacı,G.Kandemir,A.Öztürk,Ö Sayan
- The efficacy of helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura the first study in Turkey. Acta Hematologica 116,146-149,2006 O.Sayan,Erikçi A,Ozturk A
- Pretreatment haemoglobin concentration is a prognostic factor in patients with early stage breast cacer. J Int Med Res. 33; 319-328,2005 Kandemir E.G,Mayadağlı A,Türken O,Yaylacı M,Özturk A.
- The seroprevelance of viral infections and their effects on immune system in Turkish Haemophilic patients. Haemophilia 9,655-656, 2003 O.Türken,E.Solmazgül,S.Sipahi,A.Öztürk,H.Öztürkeri.
- Prevalence and prognostic value of c-erbB2 expression in non small cell lung cancer. Neoplasma 50,257-261,2003 O.Türken,E.Kunter,H.Çermik,T.Işıtmangil,M.Yaylacı,A.Öztürk.
- Breast cancer in association with thyroid disorders. Breast Cancer Reserch 5,110-113,2003. O.Türken,Y.Narin,S.Demirbaş,M:E.Önde,Ö.Sayan,E.G.Kandemir, M.Yaylacı, A.Öztürk
- Evaluation of CA-125 as a prognostic marker in Non-Hodgkin’s Lymphoma. Turkish Journal of Oncology 17:151-154,2002. O.Türken,Y.Narin,G.Kandemir,M.Yaylacı,A.Öztürk,B.Orhan
- Prognostic significance of c-erb B-2 (HER 2/neu) Expression in Early Stage Breast Cancer and its relationship with other prognostic factors Turkish Journal of Oncology 17:166-170,2002 O.Türken , Y.Kayacı , G.Kandemir , M.Yaylacı ,A.Öztürk N.Üskent
